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Objective: To evaluate the role of transarterial chemoembolization ‘‘TACE”, radiofrequency
ablation ‘‘RFA” and combination of both techniques in management of hepatocellular car-
cinoma ‘‘HCC”. Patients and methods: This study was carried out at Al-Azhar University
Hospital (New Damietta) during the period from May 2013 to June 2015. It included forty
patients were included in this study (27 males and 13 females), with age ranged from 43 to
68 year (mean age 51 year). They were divided into three groups after laboratory and radi-
ological assessment: group 1 treated with TACE, group 2 treated with RFA and group 3
treated with combined therapy. The response was evaluated by triphasic MDCT, alpha-
fetoprotein as well as clinical follow-up and classified as complete and partial response,
and the overall survival was recorded. Results: There were no major complications
detected. At 3 month follow-up, there was complete response ‘‘CR” in 32 patients (80%),
and partial response ‘‘PR” in 8 patients (20%). At 6 months, there was complete response
in 34 patients (85%), and partial response in 3 patients (7.5%). At 12 months, there was
complete response in 33 patients (82.5%), and partial response in one patient (2.5%). It is
proved that complete response with high percentage achieved by combined therapy than
either by TACE or by RFA (100%, 88.46% and 75% respectively), with the overall survival was
85%. Conclusion: The study showed that combined therapy achieved better results regard-
ing complete response and overall survival rate than RF or TACE alone.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by
Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).1. Introduction death worldwide. Considering management of HCC is aHepatocellular carcinoma (HCC) constitutes the
majority of primary liver tumors, which is the 6th most
common tumor and the 3rd most common cause of cancerchallenge, it was reported that a great number of HCC
patients are suitable for curative therapy due, either to
advanced stage of disease or to poor liver functions at time
of the diagnosis [1]. In treatment of hepatocellular
carcinoma (HCC), less than 40% of patients are candidates
for surgery in early stages, and the rate of recurrence after
curative surgery is high [2].
So, different strategies are available or being developed for
locoregional therapy, but the largest experience is with
transarterial chemoembolization (TACE) and radiofrequency
ablation (RFA). RFA is awell-studiedprocedureproducingbet-
ter local tumor control with 2 year recurrence of 2–18% and
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havebeen selected [3]. RFA is aminimally invasive, repeatable
procedurewith few complications. It is performedunder radi-
ological guidance [4].
Hepatic arterial chemoembolization (TACE) is one of the
most common treatments for unresectable hepatocarci-
noma [5]. Each of both techniques has its constrictions
and limitations depending on the tumor growth pattern,
size and number of tumors, location and number of seg-
ments involved, and response to TACE [6]. It had been
reported that RFA in combination with TACE is an effective
treatment for inoperable hepatic tumors as it can theoret-
ically overcome the limitations of each technique when
used alone [7,8].
In this study we evaluated both techniques either
separately or as combined therapy in treatment of HCC.2. Patients and methods
This study was carried out on forty patients (27 males
and 13 females), with age ranged from 43 to 68 year and
the mean age 51 year. The patients were referred to
Radiology Department from General Surgery and Internal
Medicine Departments as well as outpatient clinics. Local
Ethical Committee approval and patients’ consents were
obtained.2.1. Pre-treatment assessment
All patients were subjected to the following:
2.1.1. Complete clinical assessment
2.1.1.1. Laboratory evaluation.
 Liver profile (serum bilirubin, transaminases, alkaline
phosphatase and albumin).
 Coagulation profile (prothrombin time, concentration
and INR).
 Complete blood picture to detect thrombocytopenia.
 Alpha feto-protein (AFP).
 Viral hepatitis seromarkers: HBV seromarkers and HCV
antibodies.
2.1.1.2. Radiological assessment.
A. Abdominal ultrasonography for detection of HCC
with assessment of hepatic echogenicity, hepatic
veins, portal vein radicles and focal lesions were
commented upon. As regard the focal lesions, their
number, location, echogenicity and size measured
in two diameters were assessed. Examination of
the rest of the abdominal organs and the presence
of ascites.
B. Triphasic MDCT scan pre and post procedure, while
triphasic MDCT exam. Protocol included the usual
triphasic liver protocol in which pre-contrast images
were obtained; then, images were acquired 20 s,
55 s, and approximately 1–3 min after the
start of injection of 100 mL contrast at a rate of
4–5 mL/s.Inclusion criteria were as follows:
(a) Patent with non-thrombosed portal vein and liver
functions (ALT or AST < 270 IU/L, Albumen > 2.5 g/dl,
Bilirubin < 3 mg/dl). (b) No extrahepatic disease. (c)
The presence of a single hepatic lesion or multiple
lesions (up to 4 lesions 63 cm each). (d) Accessible site
by US and/or CT (in patients with RF treatment). (e)
Coagulation profile (prothrombin time more than 60%,
and platelet count more than 70,000/mm3). (f) Patients
should be Child’s A class or Child’s B class, and (g) Alpha
feto-protein ‘‘AFP” ranging less than 20 to more than
500 ng/mL.
Exclusion criteria were as follows:
(a) Distant metastatic. (b) Thrombosed portal vein. (c)
Poor liver functions (Bilirubin > 3 mg/dL, Albumen <
2.5 g/dL, ALT or AST > 250 IU/L). (d) Severe debilitation.
(e) Active infection, and (f) Poor coagulation profile
(prothrombin time less than 60% and platelet count less
than 70,000/mm3).
The patients were divided into three groups based on
clinical, laboratory ‘‘liver functions” and abdominal US as
well as triphasic MDCT.
* Group one, included 26 patients treated by transarterial
chemoembolization (TACE) using mixture of
Doxorubicin 50 mg dissolved in 10 cc saline and mixed
with 8 cc lipiodol and 5 cc contrast medium (ultravist
300 mL/cc) for all of them with the same concentration.
* Group two, included 12 patients treated by thermal
ablation (RFA) using RITA RF 1500X system USA and
star burst Xli enhanced with tubing set (electrosurgical
device).
* Group three, included two patients treated by com-
bined therapy of TACE followed by RFA one week later.2.1.1.3. Post procedure care. All patients underwent
interventional procedures were hospitalized overnight for
observation of side effects and administration of medica-
tions as needed. The patients were discharged within
24 h if no side effects were noted.2.1.1.4. Follow up. Three, Six and 12 months after the pro-
cedure, the follow-up included the following:
(A) Clinical: to assess improvement of symptoms such
as fever, abdominal pain, anemia, dyspepsia and
abdominal distension.
(B) Laboratory: for monitoring of AFP and liver function
tests.
(C) Imaging: radiological assessment including US and
triphasic CT scan.
Tumor response to treatment was classified into
complete and partial response, assessed by imaging and
AFP values. At imaging tumor response was measured
according to the criteria adopted by the European
Table 2
Distribution of the studied cases regarding Alpha Feto-protein level (AFP).
Alpha Feto-protein level No Percentage
<20 ng/mL 4 cases 10
21–500 ng/mL 29 cases 72.5
>500 ng/mL 7 cases 17.5
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suring the longest diameter of the viable tumor against the
longest total tumor diameter. The percentage of tumor
necrosis was also recorded. The necrotic area was identi-
fied when a low density/low-echogenicity/fluid signal area
that was non-enhancing in any of the time phases was
seen. The EASL has officially recommended the use of
contrast enhanced CT in the evaluation of response to
treatment, and acknowledged as ‘‘viable areas” those that
‘‘present enhancement” and ‘‘necrotic areas” those that
‘‘do not present enhancement”. The EASL response criteria
were preferred since they take into account the develop-
ment of necrosis and not only the size of the treated lesion
as in Response Evaluation Criteria in Solid Tumor (RECIST)
criteria (which depends only on shrinkage in size) since it
acknowledged that it is common for liver tumors to liquefy
without a significant change in total lesion diameter
within short follow-up periods. In EASL criteria, complete
response (CR) is recorded when complete disappearance
of all known disease and no new lesions are seen; partial
response (PR) when a 50% reduction in viable tumoral area
of all measurable lesions is present; stable disease (SD) in
all other cases and progressive disease (PD) when there
is a 25% increase in size of one or more measurable lesions
or if new lesions appear [9].
MDCT images were reviewed by two radiologists. In
cases the residual viable tumor was at least 1 cm in maxi-
mum axial diameter, and further treatment was scheduled.3. Results
Frequency and percentages of liver cirrhosis and Child-
Pugh classification in the whole sample (Table 1).
These AFP levels had been decreased in most patients to
be less than 20 ng/mL after interventional procedures
except in 5 patients ranging from 50 to 100 ng/mL (see
Table 2).Table 3
Patients’ response according to EASL criteria at 3, 6, and 12 months.
Response TACE
(n = 26)
RFA
(n = 12)
Combined
Th. (n = 2)
3 months
Complete response 20 (76.92%) 10 (83.33%) 2 (100%)
Partial response 6 (23.07%) 2 (16.66%) 0 (0%)3.1. Group one, included 26 patients treated by TACE
This group showed 24 patients Child’s A class and two
patients Child’s B class. 20 patients of them had solitary
tumor and 6 patients had multiple tumors. TACE sessions
ranged from 1 to 3 sessions. There was complete response
in 20 patients after 3 months (76.92%), while partial
response was seen in 6 patients (23.07%). Two out of the
6 patients died after 3 months, and two out of the 4
patients showed complete response (CR). So the sum 22
at 6 months, one of the other 2 patients died afterTable 1
Etiology and classification of cirrhosis.
Variant Frequency Percentage
Etiology of cirrhosis HBV 2 5
HCV 37 92.5
HCV + HBV 1 2.5
Child – Pugh Classification Child’s A 37 92.5
Child’s B 3 7.5
Child’s C 0 06 months and one patient showed partial response (PR)
by the end of the year, hence the sum 23 (22 showed CR
and one showed PR). Consider addition of the 2 patients
treated by combined therapy, so the sum is 25 patients
(24 showed complete response ‘‘CR” and one showed par-
tial response ‘‘PR”).
3.2. Group two, included 12 patients treated by thermal
ablation (RFA)
This group showed 11 patients Child’s A class and one
patient Child’s B class. Eleven patients had solitary tumor
and one patient had multiple tumors. RFA sessions were
repeated on demand 1–3 sessions. After 3 months, there
was complete response in 10 patients (83.33%), and par-
tial response was seen in 2 patients (16.66%). 1/10
patients died after 5 months and further 2/2 patients died
after 10 months. Hence the sum is 9 survive patients
(75%) at the end of one year (all of them showed com-
plete response ‘‘CR”).
3.3. Group three, included two patients treated by combined
RFA after TACE
– All patients were Child’s A class with solitary tumor.
Complete necrosis was achieved following the first ses-
sion in the two patients without further sessions (100%)
(see Table 3).
3.4. Complications of TACE
A. Immediate post-treatment side effects (PTS):
PTS (fever <38 C, pain, anorexia, nausea and vomiting)
occurred in 21 patients (80.7%), all of them recoveredStable disease 0 (0%) 0 (0%) 0 (0%)
Progressive disease 0 (0%) 0 (0%) 0 (0%)
6 months
Complete response 22 (84.6%) 9 (75%) 2 (100%)
Partial response 2 (7.7%) 2 (16.66%) 0 (0%)
Stable disease 0 (0%) 0 (0%) 0 (0%)
Progressive disease 2 (7.7%) 1 (8.33%) 0 (0%)
12 months
Complete response 22 (84.61%) 9 (75%) 2 (100%)
Partial response 1 (3.84%) 0 (0%) 0 (0%)
Stable disease 0 (0%) 0 (0%) 0 (0%)
Progressive disease 3 (11.53%) 3 (25%) 0 (0%)
Table 4
Survival percentages of all 40 patients at 3, 6 and 12 months.
Groups Group I treated by TACE (26 cases) Group II treated by thermal
ablation (12 cases)
Group III treated by RF after TACE
(2 cases)
Survival
Months 3 6 12 3 6 12 3 6 12
Number of cases 26 24 23 12 11 9 2 2 2
Frequency 100% 92.3% 88.46% 100% 91.66% 75% 100% 100% 100%
Fig. 1. 58 years-old male with hepatic focal lesion diagnosed HCC ‘‘treated by TACE”. (A) Contrast enhanced CT shows an enhanced lesion at segment IV. (B)
TACE showed adequate lipiodol concentration within the lesion. (C) Three months post TACE non-contrast CT study revealed inadequate accumulation of
lipiodol within the tumor. Triphasic CT showed small foci of lipiodol with arterial enhancement of the lesion in arterial phase (D) and washout in portal
phase (E) and delayed phase (F) denotes inadequate ablation (partial response). AFP = 258 ng/mL before TACE and 200 ng/mL three months after. The
patient referred to surgery for tumor resection.
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antipyretic and antiemetic.
B. Late post-treatment side effects:
Decompensation occurred in 2 patients in the form of
ascites and mild increase in the liver enzymes (treated
medically). Liver abscess, cholecystitis, pleural effusion
and CNS problems were not recorded in any patient till
the end of the study.
3.4.1. Complications of thermal ablation (RFA)
Nearly all the patients experienced post-ablation right
hypochondrial pain that was controlled by analgesics,and nausea, which was controlled by anti-emetics. Also
all patients experienced post-ablation pyrexia for 2 days,
which was controlled by antipyretics. Major post procedu-
ral complications were one patient with reactionary effu-
sion, two patients had ascites and liver decompensation
and five patients with subcapsular hematoma (see
Table 4).
The survival status of all 40 patients was evaluated and
reported at 3, 6 and 12 months after treatment. Four
patients died from advanced decompensated liver disease,
and two patients died from coexisting concomitant illness
(chest and cardiac diseases). The overall survival after
treatment with combined therapy, TACE and RFA was
100%, 88.46%, and 75% respectively (see Figs. 1–3).
Fig. 2. 54 years-old female with focal lesion diagnosed HCC and treated by RFA. (A) Contrast enhanced CT shows an enhanced lesion at segment VII. Follow-
up with Triphasic CT showed no enhanced residual lesion in arterial phase (B) and no washout in portal phase (C) or delayed phase (D) denoting good
ablation. AFP = 15 ng/mL before treatment and decreased to <5 ng/mL three months after treatment.
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High incidence rate of HCC has been reported in Egypt.
Several studies were done on the association between HCV
and HCC [10,11]. Yates et al. [12] found that among Egyp-
tian patients with HCC more than 75% were positive for
HCV-Ab. Nearby results (70%) were reported by Darwish
et al. [13]. Patients with liver cirrhosis are at greatest risk
for developing HCC and should be monitored every
6 months to detect the tumor at an asymptomatic stage
[14]. Locoregional therapeutic modalities have been devel-
oped and tested clinically over the recent years for treat-
ment of HCC [15]. Several studies have shown that RF
ablation (RFA) is a simple, effective, and less expensive
technique with a low morbidity compared with surgical
treatment [16].
In this study, follow-up of the patients over one-year
duration, included reporting the response either completeor partial (CR, PR), recurrent diseases ‘‘RD” and progression
diseases ‘‘PD”.
High percentage of complete response (83.33%) in
patients underwent RF ablation ‘‘10/12” after one session.
One of the two patients showed complete necrosis after a
second session and the other one died; this agreed with
report by Raut et al. [17].
Teratani et al. [18] reported that RFA for patients with
small HCC nodules (less than 5 cm) provides favorable sur-
vival with excellent local control. Good response with
those underwent RF alone at 3, 6, and 12 months was
100%, 91.66% and 75% respectively. This was in accordance
with Chen et al. [19] who reported RFA success rate 93.3%,
84.6% and 66.6% respectively.
All patients exposed to RFA experienced post-ablation
right hypochondrial pain and nausea that was controlled
by analgesics and anti-emetics. Major post procedural
complications were one patient with reactionary effusion,
Fig. 3. 45 years-old male with HCC and treated by combined therapy using TACE and RFA. (A) Post-contrast CT showed enhanced lesion at segment V of
right lobe. (B) TACE shows inadequate lipiodol accumulation within the lesion. Three months after TACE, non-enhanced CT revealed a lesion with poor
accumulation of lipiodol in (C) and enhanced lesion ‘‘post contrast CT” in (D). Three months post RF: Arterial phase revealed no enhancement of the lesion in
(E), and no washout in portal phase (F) or delayed phase (G) denoting adequate ablation. AFP = 58 ng/mL before treatment and decreased to <20 ng/mL
three months after treatment.
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this was in accordance with other reports [20,21].
Use of TACE showed complete response in 20/26
(76.92%) after one session, while partial response in 6
patients (23.07%) after second session. Three out of the 6
patients died (11.53%), 2 showed complete response(7.7%) and one (3.8%) showed partial response. This agreed
with reports used TACE as an effective palliative treatment
for unresectable tumors [22,23].
Regarding post TACE complications in this study, PES
(fever <38 C, pain, anorexia, nausea and vomiting)
occurred in 21/26 (80.7%) and recovered within 3 days
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etiology of PES is not fully understood but it is thought to
be caused by combination of tissue ischemia and an
inflammatory response to chemoembolization [24]. Late
post-treatment side effects appear in the form of liver
decompensation with ascites and increased liver enzymes.
All of them received one session of TACE and treated med-
ically [25]. Patients needed a second sessions of TACE or
RFA are those who showed partial response after first
session.
Combined therapy showed complete necrosis after one
session with no need for further sessions and overall sur-
vival rate 100%. However, there were no recurrent lesions
detected in combined therapy group.
The overall survival rate was 88.46% in TACE group, 75%
in RFA group and 100% in combined therapy group; this
agreed with Lo et al. [26] who reported a study of 40
patients assigned to chemoembolization with near survival
probability of 82%, and higher than study by Othman et al.
[27] who reported survival rates 75% with TACE, 90% with
RFA and 95% with combined therapy.
Post therapy follow-up of Alpha feto-protein showed
that it was decreased gradually to near normal levels in
those patients showed complete response, that agreed
with reports stated by Hu et al. [28].
From this study it was noted that combined therapy is
superior to either TACE or RFA regarding complete response
and survival. TACE has been used to minimize heat loss due
toperfusionmediated tissue cooling and to increase the ther-
apeuticeffectofRFablation, thus increasing the rangeof ther-
apeutic isotherms because of a greater sensitivity of
neoplastic cells to hyperthermia [29]. HCC therapy can be
divided according to the stage of the disease and degree of
liver impairment into curative versus palliative approaches.
Curative treatments are reserved for patients without portal
vein invasion or distant metastases. Palliative therapy via
transarterial chemoembolization (TACE) may be offered for
unresectable HCC [30]. The patients should be monitored
regularly for exclusion of intrahepatic newly developed/
recurrent lesions by follow-up protocol including enhanced
MDCT examinations and tumor markers.
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